Frost Radar: Artificial Intelligence-Enabled Clinical Trials, 2026

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

Artificial intelligence (AI) has been revolutionizing the technology-enabled drug discovery and development landscape. In clinical research, AI has been gaining traction across site selection, trial design and protocol optimization, and patient recruitment and management. Because data is the core discipline of drug development, electronic medical records and real-world evidence also support trial outcomes and improve drug efficiency. AI can create structured databases from disparate and unstructured sources, simplifying data assessment and enhancing trial safety and efficiency. Sophisticated generative and agentic AI-based technologies and real-world data and copilot-based large language models provide real-time database access to target the right patient to the right clinical trial.

AI-driven solutions used in clinical trial design, site selection, and patient identification and retention can reduce costs, increase efficiency, and support the transition to decentralized trials by means of remote patient recruitment, management, and engagement. Interactive platforms ensure better patient adherence and greater retention. For this Frost Radar analysis, Frost & Sullivan selected companies that reflect a sharp focus on innovative AI technologies for clinical trial support and real-world evidence generation and access and a goal to overcome the key challenges across the highly mature clinical trials industry.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.